CN110621659B - (+)-3-(2,3-二氟苯基)-3-甲氧基吡咯烷或其药学上可接受的盐、其制备方法及其用途 - Google Patents

(+)-3-(2,3-二氟苯基)-3-甲氧基吡咯烷或其药学上可接受的盐、其制备方法及其用途 Download PDF

Info

Publication number
CN110621659B
CN110621659B CN201880031878.8A CN201880031878A CN110621659B CN 110621659 B CN110621659 B CN 110621659B CN 201880031878 A CN201880031878 A CN 201880031878A CN 110621659 B CN110621659 B CN 110621659B
Authority
CN
China
Prior art keywords
salt
formula
disorders
compound
formula lib
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880031878.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN110621659A (zh
Inventor
C·索尼森
M·布克萨
I·雷尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NTG Nordic Transport Group AS
Original Assignee
Neurosearch AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurosearch AS filed Critical Neurosearch AS
Publication of CN110621659A publication Critical patent/CN110621659A/zh
Application granted granted Critical
Publication of CN110621659B publication Critical patent/CN110621659B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/11—Compounds covalently bound to a solid support
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
CN201880031878.8A 2017-05-19 2018-05-18 (+)-3-(2,3-二氟苯基)-3-甲氧基吡咯烷或其药学上可接受的盐、其制备方法及其用途 Active CN110621659B (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP17171938 2017-05-19
EP17171938.8 2017-05-19
EP17195451.4 2017-10-09
EP17195451 2017-10-09
EP17207406 2017-12-14
EP17207406.4 2017-12-14
EP18151428 2018-01-12
EP18151428.2 2018-01-12
PCT/EP2018/063123 WO2018211080A1 (en) 2017-05-19 2018-05-18 (+)-3-(2,3-difluorophenyl)-3-methoxypyrrolidine or pharmaceutically acceptable salts thereof, a process for preparation thereof and uses thereof

Publications (2)

Publication Number Publication Date
CN110621659A CN110621659A (zh) 2019-12-27
CN110621659B true CN110621659B (zh) 2023-02-28

Family

ID=62599537

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880031878.8A Active CN110621659B (zh) 2017-05-19 2018-05-18 (+)-3-(2,3-二氟苯基)-3-甲氧基吡咯烷或其药学上可接受的盐、其制备方法及其用途

Country Status (10)

Country Link
US (3) US11078158B2 (enExample)
EP (1) EP3625213B1 (enExample)
JP (1) JP7126522B2 (enExample)
CN (1) CN110621659B (enExample)
CA (1) CA3064136A1 (enExample)
DK (1) DK3625213T3 (enExample)
ES (1) ES2943252T3 (enExample)
FI (1) FI3625213T3 (enExample)
PL (1) PL3625213T3 (enExample)
WO (1) WO2018211080A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020239568A1 (en) * 2019-05-24 2020-12-03 Integrative Research Laboratories Sweden Ab Pharmaceutically acceptable salts of [2-(3-fluoro-5-methane-sulfonylphenoxy)ethyl](propyl)amine and uses thereof
CA3180417A1 (en) * 2020-06-10 2021-12-16 Guillaume Dutheuil Synthesis of (2s,5r)-5-(2-chlorophenyl)-1-(2'-methoxy-[1,1'-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid
WO2025003437A1 (en) 2023-06-28 2025-01-02 Integrative Research Laboratories Sweden Ab A pharmaceutical composition comprising a fumaric acid salt of (+)-3-(2,3-difluorophenyl)-3-methoxypyrrolidine

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0586229A1 (en) * 1992-09-01 1994-03-09 Zeneca Limited 3-Hydroxy-3-(subst-akyl)-pyrrolidines as 5-lipoxygenase inhibitors
CN101808987A (zh) * 2007-06-05 2010-08-18 Nsab神经研究瑞典公司分公司 作为皮层儿茶酚胺能神经传递调节剂的二取代的苯基吡咯烷
CN102224136A (zh) * 2008-11-24 2011-10-19 Nsab神经研究瑞典公司分公司 用作皮质儿茶酚胺能神经传递调节剂的3-苯基-3-甲氧基-吡咯烷衍生物
CN104447490A (zh) * 2014-11-19 2015-03-25 连云港恒运医药科技有限公司 一种质子泵抑制剂的晶型、制备中间体及其合成方法和医药用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1582524B1 (en) 2004-04-02 2008-08-13 Ludwig Maximilians Universität Method of preparing organomagnesium compounds

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0586229A1 (en) * 1992-09-01 1994-03-09 Zeneca Limited 3-Hydroxy-3-(subst-akyl)-pyrrolidines as 5-lipoxygenase inhibitors
CN101808987A (zh) * 2007-06-05 2010-08-18 Nsab神经研究瑞典公司分公司 作为皮层儿茶酚胺能神经传递调节剂的二取代的苯基吡咯烷
CN102224136A (zh) * 2008-11-24 2011-10-19 Nsab神经研究瑞典公司分公司 用作皮质儿茶酚胺能神经传递调节剂的3-苯基-3-甲氧基-吡咯烷衍生物
CN104447490A (zh) * 2014-11-19 2015-03-25 连云港恒运医药科技有限公司 一种质子泵抑制剂的晶型、制备中间体及其合成方法和医药用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Pyrrolidines. IX. 3-Aryl-3-pyrrolidinols;William A. Gould et al.;《J. Med. Chem.》;19640101;第7卷(第1期);第60-67页 *

Also Published As

Publication number Publication date
FI3625213T3 (fi) 2023-05-29
US12091384B2 (en) 2024-09-17
CA3064136A1 (en) 2018-11-22
ES2943252T3 (es) 2023-06-12
US20240400505A1 (en) 2024-12-05
CN110621659A (zh) 2019-12-27
JP2020520936A (ja) 2020-07-16
PL3625213T3 (pl) 2023-07-17
US20200024231A1 (en) 2020-01-23
DK3625213T3 (da) 2023-04-24
JP7126522B2 (ja) 2022-08-26
EP3625213A1 (en) 2020-03-25
EP3625213B1 (en) 2023-03-08
WO2018211080A1 (en) 2018-11-22
US11078158B2 (en) 2021-08-03
US20210317081A1 (en) 2021-10-14

Similar Documents

Publication Publication Date Title
JP7476115B2 (ja) 新規の塩および結晶
EP3687535B1 (en) Crystalline hydrochloride salt of lumateperone
US20240400505A1 (en) (+)-3-(2,3-difluorophenyl)-3-methoxypyrrolidine or pharmaceutically acceptable salts thereof, a process for preparation thereof and uses thereof
CN108699063A (zh) 一种芦可替尼的合成工艺
US20230312573A1 (en) Novel salts, crystals, and co-crystals
KR20230021075A (ko) 베타 아드레날린성 작용제의 형태 및 조성물
EP1268466A1 (en) Decahydro-isoquinolines
CN113853369B (zh) [2-(3-氟-5-甲磺酰基苯氧基)乙基](丙基)胺的药学上可接受的盐及其用途
EP3057963B1 (en) Piperazine derivatives and the use thereof as medicament
KR102768447B1 (ko) (-)-시벤졸린 숙신산염의 신규한 제조 공정
HK40012481A (en) (+)-3-(2,3-difluorophenyl)-3-methoxypyrrolidine or pharmaceutically acceptable salts thereof, a process for preparation thereof and uses thereof
HK40012481B (en) (+)-3-(2,3-difluorophenyl)-3-methoxypyrrolidine or pharmaceutically acceptable salts thereof, a process for preparation thereof and uses thereof
Sugane et al. Practical and efficient synthesis of the (R)-atropisomer of a 4-phenyl 1, 2, 4-triazole derivative as a selective GlyT1 inhibitor
TWI886914B (zh) -3-酮衍生物枸櫞酸鹽的晶型、製備方法及其用途
KR102892833B1 (ko) [2-(3-플루오로-5-메탄-술포닐페녹시)에틸](프로필)아민의 제약상 허용되는 염 및 그의 용도
CN111902406B (zh) 氮杂双环基取代的三唑类衍生物的可药用盐、晶型及制备方法
HK40091613A (zh) 新的盐、晶体和共晶体
CN118206501A (zh) 一种卢吗哌酮的制备方法
JP2025513526A (ja) ５Ｈピロロ［２，３－ｂ］ピラジン誘導体の多形形態、それらの調製方法、及び使用
CN118878427A (zh) 一种制备瑞波替尼中间体的方法
EA047399B1 (ru) Фармацевтически приемлемые соли [2-(3-фтор-5-метансульфонилфенокси)этил](пропил)амина и их применение
JP2012520345A (ja) Ｎ−［（２−アザ−ビシクロ［２．１．１］ヘキス−１−イル）−アリール−）メチル］−ヘテロベンズアミドの誘導体、その調製および治療におけるその用途
JP2012517411A (ja) Ｎ−［（２−アザビシクロ［２．１．１］ヘキス−１−イル）−アリール−メチル］−ベンズアミド誘導体類、これらの製造およびこれらの治療使用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40012481

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant